Abstract
The emergence of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak, which causes COVID-19, had a devastating impact on both people’s lives and the global economy. During the course of the pandemic, the lack of specific drugs or treatments tailored for COVID-19 led to extensive repurposing of existing drugs in the pursuit of effective treatments. Some drug molecules demonstrated efficacy, while others proved ineffective. In this context, the approach of drug repurposing emerged as a novel strategy for combating COVID-19. Repurposed drugs and biologics have shown effectiveness, leading to improved clinical outcomes among patients with COVID-19. Similarly, It is equally important to assess the risk–benefit ratio associated with drugs and biologics adapted for COVID-19 treatment. Herein, we primarily focus on evaluating adverse drug events linked to repurposed COVID-19 medications, repurposed biologics, and COVID-specific drug molecules.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
No datasets were generated or analysed during the current study.
References
ACTIV-3/TICO Study Group*, Barkauskas C, Mylonakis E, Poulakou G, Young BE, Vock DM, Siegel L, Engen N, Grandits G, Mosaly NR, Vekstein AM, Rogers R, Shehadeh F, Kaczynski M, Mylona EK, Syrigos KN, Rapti V, Lye DC, Hui DS, Leither L, Knowlton KU, Jain MK, Marines-Price R, Osuji A, Overcash JS, Kalomenidis I, Barmparessou Z, Waters M, Zepeda K, Chen P, Torbati S, Kiweewa F, Sebudde N, Almasri E, Hughes A, Bhagani SR, Rodger A, Sandkovsky U, Gottlieb RL, Nnakelu E, Trautner B, Menon V, Lutaakome J, Matthay M, Robinson P, Protopapas K, Koulouris N, Kimuli I, Baduashvili A, Braun DL, Günthard HF, Ramachandruni S, Kidega R, Kim K, Hatlen TJ, Phillips AN, Murray DD, Jensen TO, Padilla ML, Accardi EX, Shaw-Saliba K, Dewar RL, Teitelbaum M, Natarajan V, Laverdure S, Highbarger HC, Rehman MT, Vogel S, Vallée D, Crew P, Atri N, Schechner AJ, Pett S, Hudson F, Badrock J, Touloumi G, Brown SM, Self WH, North CM, Ginde AA, Chang CC, Kelleher A, Nagy-Agren S, Vasudeva S, Looney D, Nguyen HH, Sánchez A, Weintrob AC, Grund B, Sharma S, Reilly CS, Paredes R, Bednarska A, Gerry NP, Babiker AG, Davey VJ, Gelijns AC, Higgs ES, Kan V, Matthews G, Thompson BT, Legenne P, Chandra R, Lane HC, Neaton JD, Lundgren JD, Barkauskas C, Mylonakis E, Poulakou G, Young BE, Vock DM, Siegel L, Engen N, Grandits G, Mosaly NR, Vekstein AM, Rogers R, Shehadeh F, Kaczynski M, Mylona EK, Syrigos KN, Rapti V, Lye DC, Hui DS, Leither L, Knowlton KU, Jain MK, Marines-Price R, Osuji A, Overcash JS, Kalomenidis I, Barmparessou Z, Waters M, Zepeda K, Chen P, Torbati S, Kiweewa F, Sebudde N, Almasri E, Hughes A, Bhagani SR, Rodger A, Sandkovsky U, Gottlieb RL, Nnakelu E, Trautner B, Menon V, Lutaakome J, Matthay M, Robinson P, Protopapas K, Koulouris N, Kimuli I, Baduashvili A, Braun DL, Günthard HF, Ramachandruni S, Kidega R, Kim K, Hatlen TJ, Phillips AN, Murray DD, Jensen TO, Padilla ML, Accardi EX, Shaw-Saliba K, Dewar RL, Teitelbaum M, Natarajan V, Laverdure S, Highbarger HC, Rehman MT, Vogel S, Vallée D, Crew P, Atri N, Schechner AJ, Pett S, Hudson F, Badrock J, Touloumi G, Brown SM, Self WH, North CM, Ginde AA, Chang CC, Kelleher A, Nagy-Agren S, Vasudeva S, Looney D, Nguyen HH, Sánchez A, Weintrob AC, Grund B, Sharma S, Reilly CS, Paredes R, Bednarska A, Gerry NP, Babiker AG, Davey VJ, Gelijns AC, Higgs ES, Kan V, Matthews G, Thompson BT, Legenne P, Chandra R, Lane HC, Neaton JD, Lundgren JD, Sahner D, Tierney J, Herpin BR, Smolskis MC, McKay LA, Cahill K, Sardana R, Raim SS, Hensely L, Lorenzo J, Mock R, Zuckerman J, Miller M, Chung L, Kang N, Adam SJ, Read S, Draghia-Akli R, Carlsen A, Carter A, Denning E, DuChene A, Eckroth K, Frase A, Gandits G, Harrison M, Kaiser P, Koopmeiners J, Meger S, Murray T, Quan K, Quan SF, Thompson G, Walski J, Wentworth D, Moskowitz AJ, Bagiella E, Moquete E, O’Sullivan K, Marks ME, Kinzel E, Burris S, Bedoya G, Gupta L, Overbey JR, Padillia ML, Santos M, Gillinov MA, Miller MA, Taddei-Peters WC, Fenton K, Mack M, Berhe M, Haley C, Dishner E, Bettacchi C, Golden K, Duhaime E, Ryan M, Burris S, Tallmadge C, Estrada L, Jones F, Villa S, Wang S, Robert R, Coleman T, Clariday L, Baker R, Hurutado-Rodriguez M, Iram N, Fresnedo M, Davis A, Leonard K, Ramierez N, Thammavong J, Duque K, Turner E, Fisher T, Robinson D, Ransom D, Maldonado N, Lusk E, Killian A, Palacious A, Solis E, Jerrow J, Watts M, Whitacre H, Cothran E, Smith PK, Ko ER, Dreyer GR, Stafford N, Brooks M, Der T, Witte M, Gamarallage R, Franzone J, Ivey N, Lumsden RH, Mourad A, Holland TL, Motta M, Lane K, McGowan LM, Stout J, Aloor H, Bragg KM, Toledo B, McLendon-Arvik B, Bussadori B, Hollister BA, Griffin M, Giangiacomo DM, Rodriguez V, Parrino PE, Spindel S, Bansal A, Baumgarten K, Hand J, Vonderhaar D, Nossaman B, Laudun S, Ames D, Broussard S, Hernandez N, Isaac G, Dinh H, Zheng Y, Tran S, McDaniel H, Crovetto N, Perin E, Costello B, Manian P, Sohail MR, Postalian A, Hinsu P, Watson C, Chen J, Fink M, Sturgis L, Kim W, Mahon K, Parenti J, Kappenman C, Knight A, Sturek JM, Barros A, Enfield KB, Kadl A, Green CJ, Simon RM, Fox A, Thornton K, Adams A, Traverse JH, Rhame F, Huelster J, Kethireddy R, Salamanca J, Majeski C, Skelton P, Zarambo M, Sarafolean A, Oldmixon C, Ringwood N, Muzikansky A, Morse R, Brower RG, Reineck LA, Aggarwal NR, Bienstock K, Steingrub JH, Hou PK, Steingrub JS, Tidswell MA, Kozikowski L-A, Kardos C, DeSouza L, Romain S, Talmor D, Shapiro N, Andromidas K, Banner-Goodspeed V, Bolstad M, Boyle KL, Cabrera P, deVilla A, Ellis JC, Grafals A, Hayes S, Higgins C, Kurt L, Kurtzman N, Redman K, Rosseto E, Scaffidi D, Shapiro N, Talmor D, Filbin MR, Hibbert KA, Parry B, Margolin J, Hillis B, Hamer R, Jones AE, Galbraith J, Nandi U, Hendey G, Matthay MA, Kangelaris K, Ashktorab K, Gropper R, Agrawal A, Almasri E, Fayed M, Hubel KA, Garcia RL, Lim GW, Chang SY, Hendey G, Lin MY, Vargas J, Sihota H, Beutler R, Rogers AJ, Wilson JG, Vojnik R, Perez C, McDowell JH, Albertson T, Hardy E, Harper R, Moss MA, Ginde AA, Chauhan L, Douin DJ, Martinez F, Finck LL, Bastman J, Hyzy RC, Park PK, Hyzy RC, Park PK, Nelson K, McSparron JI, Co IN, Wang BR, Jimenez J, Sullins B, Olbrich N, Gong MN, Richardson LD, Gong MN, Nair R, Lopez B, Amosu O, Tzehaie H, Nkemdirim W, Boujid S, Mosier JM, Hypes C, Campbell ES, Bixby B, Gilson B, Lopez A, Hite RD, Terndrup TE, Wiedemann HP, Hudock K, Tanzeem H, More H, Martinkovic J, Sellers S, Houston J, Burns M, Hough CL, Robinson BH, Hough CL, Khan A, Krol OF, Mills E, Kinjal M, Briceno G, Reddy R, Hubel K, Parimon T, Caudill A, Mattison B, Jackman SE, Chen P-E, Bayoumi E, Ojukwu C, Fine D, Weissberg G, Isip K, Choi-Kuaea Y, Mehdikhani S, Dar TB, Augustin NBF, Tran D, Dukov JE, O’Mahony DS, Wilson DM, Wallick JA, Duven AM, Fletcher DD, Files DC, Miller C, Gibbs KW, Flores LS, LaRose ME, Landreth LD, Palacios DR, Parks L, Hicks M, Goodwin AJ, Kilb EF, Lematty CT, Patti K, Bledsoe J, Brown S, Lanspa M, Pelton I, Armbruster BP, Montgomery Q, Kumar N, Fergus M, Imel K, Palmer G, Webb B, Klippel C, Jensen H, Duckworth S, Gray A, Burke Tyler, Knox D, Lumpkin J, Aston VT, Rice TW, Self WH, Rice TW, Casey JD, Johnson J, Hays M, Kasubhai M, Pillai A, Daniel J, Sittler D, Kanna B, Jilani N, Amaro F, Santana J, Lyakovestsky A, Madhoun I, Desroches LM, Amadon N, Bahr A, Ezzat I, Guerrero M, Padilla J, Fullmer J, Singh I, Ali Shah SH, Narang R, Mock P, Shadle M, Hernandez B, Welch K, Payne A, Ertl G, Canario D, Barrientos I, Goss D, DeVries M, Folowosele I, Garner D, Gomez M, Price J, Bansal E, Wong J, Faulhaber J, Fazili T, Yeary B, Ndolo R, Bryant C, Smigeil B, Najjar R, Jones P, Nguyen J, Chin C, Taha H, Najm S, Smith C, Moore J, Nassar T, Gallinger N, Christian A, Mauer D, Phipps A, Coslet J, Landazuri R, Pineda J, Uribe N, Garcia JR, Barbabosa C, Sandler K, Marquez A, Chu H, Lee K, Quillin K, Garcia A, Lew P, Tran Q-L, Benitez G, Mishra B, Felix LO, Vafea MT, Atalla E, Davies R, Hedili S, Monkeberg MA, Tabler S, Mylonakis E, Rogers R, Shehadeh F, Mylona EK, Kaczynski M, Tran Q-L, Benitez G, Mishra B, Felix LO, Vafea MT, Atalla E, Davies R, Hedili S, Harrington B, Popielski L, Kambo A, Viens K, Turner M, Vjecha MJ, Osuji A, Agbor BTA, Petersen T, Kamel D, Hansen L, Garcia A, Cha C, Mozaffari A, Hernandez R, Jain MK, Agbor BTA, Petersen T, Kamel D, Hansen L, Garcia Angie, Kim M, DellaValle N, Gonzales S, Somboonwit C, Oxner A, Guerra L, Tran T, Pinto A, Anderson B, Zepeda-Gutierrez A, Martin D, Temblador C, Cuenca A, Guerrero M, Daar E, Correa R, Hartnell G, Wortmann G, Doshi S, Moriarty T, Gonzales M, Garman K, Baker JV, Frosch A, Goldsmith R, Jibrell H, Lo M, Klaphake J, Mackedanz S, Ngo L, Garcia-Myers K, Kunisaki KM, Hassler M, Walquist M, Augenbraun M, Dehovitz J, Abassi M, Leuck A-M, Rao V, Biswas K, Harrington C, Garcia A, Bremer T, Burke Tara, Koker B, Davis-Karim A, Pittman D, Vasudeva SS, Pandit L, Hines-Munson C, Van J, Dillon L, Wang Y, Ochalek T, Caldwell E, Humerickhouse E, Boone D, McGraw W, Mehta SR, Johns ST, StJohn M, Raceles J, Sear E, Funk S, Cesarini R, Fang M, Nicalo K, Drake W, Jones B, Holtman T, Maniar A, Johnson EA, Nguyen L, Tran MT, Barrett TW, Johnston T, Huggins JT, Beiko TY, Hughes HY, McManigle WC, Tanner NT, Washburn RG, Ardelt M, Tuohy PA, Mixson JL, Hinton CG, Thornley N, Allen H, Elam S, Boatman B, Baber BJ, Ryant R, Roller B, Nguyen C, Mikail AM, Hansen M, Lichtenberger P, Baracco G, Ramos C, Bjork L, Sueiro M, Tien P, Freasier H, Buck T, Nekach H, Holodniy M, Chary A, Lu K, Peters T, Lopez J, Tan SY, Lee RH, Asghar A, Isip TKK, Le K, Nguyen T, Wong S, Raben D, Aagaard B, Nielsen CB, Krapp K, Nykjær BR, Olsson C, Kanne KL, Grevsen AL, Joensen ZM, Bruun T, Bojesen A, Woldbye F, Normand NE, Benfield T, Clausen CL, Hovmand N, Israelsen SB, Iversen K, Leding C, Pedersen KB, Thorlacius-Ussing L, Tinggaard M, Tingsgard S, Jensen J-US, Overgaard R, Rastoder E, Heerfordt C, Hedsund C, Ronn CP, Kamstrup PT, Hogsberg DS, Bergsoe C, Ostergaard L, Staerke NB, Yehdego Y, Sondergaard A, Johansen IS, Holden IK, Lindvig SO, Helleberg M, Gerstoft J, Kirk O, Bruun T, Jensen TO, Madsen BL, Pedersen TI, Harboe ZB, Roge BT, Hansen TM, Glesner MK, Lofberg SV, Nielsen AD, Nielsen H, Thisted RK, Petersen KT, Juhl MR, Podlekareva D, Johnsen S, Wiese L, Knudsen LS, Expósito M, Badillo J, Martínez A, Abad E, Chamorro A, Mateu L, España S, Lucero MC, Santos JR, Lladós G, Lopez C, Carabias L, Fernández-Cruz E, Di Natale M, Padure S, Gomez J, Ausin C, Cervilla E, Balastegui H, Sainz CR, Lopez P, Escobar M, Balerdi L, Legarda A, Roldan M, Letona L, Muñoz J, Arribas JR, Sánchez RM, Díaz-Pollán B, Stewart SM, Garcia I, Borobia A, Estrada V, Cabello N, Nuñez-Orantos MJ, Sagastagoitia I, Homen JR, Orviz E, Montalvá AS, Espinosa-Pereiro J, Bosch-Nicolau P, Salvador F, Morales-Rull JL, Pena AMM, Acosta C, Solé-Felip C, West E, M’Rabeth-Bensalah K, Eichinger ML, Grüttner-Durmaz M, Grube C, Zink V, Goes J, Tsertsvadze T, Abutidze A, Chkhartishvili N, Metchurtchlishvili R, Endeladze M, Paciorek M, Bursa D, Krogulec D, Pulik P, Ignatowska A, Fishchuk R, Kobrynska O, Levandovska K, Kirieieva I, Kuziuk M, Polizzotto M, Carey C, Dharan NJ, Hough S, Virachit S, Davidson S, Bice DJ, Ognenovska K, Cabrera G, Flynn R, Chia PY, Lee TH, Lin RJ, Ong SWX, Puah SH, Yeo TW, Ongko J, Yeo HP, Kwaghe V, Zaiyad H, Idoko G, Uche B, Selvamuthu P, Kumarasamy N, Beulah FE, Govindarajan N, Mariyappan K, Losso MH, Abela C, Moretto R, Belloc CG, Ludueña J, Amar J, Losso MH, Toibaro J, Macias LM, Fernandez L, Frare PS, Chaio SR, Pachioli V, Timpano SM, Sanchez MDL, Sierra MDP, Stanek V, Belloso W, Cilenti FL, Valentini RN, Stryjewski ME, Locatelli N, Riera MCS, Salgado C, Baeck IM, Di Castelnuovo V, Zarza SM, Parmar MKB, Goodman AL, Gregory A, Goodall K, Harris N, Wyncoll J, Luntiel A, Patterson C, Morales J, Witele E, Preston AM, Nandani A, Price DA, Nell J, Patel B, Hays C, Jones G, Davidson J, Pantazis N, Gioukari V, Souliou T, Antoniadou A, Kavatha D, Grigoropoulou S, Tziolos RN, Oikonomopoulo C, Moschopoulos C, Tzimopoulos K, Koromilias A, Argyraki K, Lourida P, Bakakos P, Vlachakos V, Balis E, Zakynthinos S, Sigala I, Gianniou N, Dima E, Magkouta S, Synolaki E, Konstanta S, Vlachou M, Stathopoulou P, Panagopoulos P, Petrakis V, Papazoglou D, Tompaidou E, Isaakidou E, Leontis K, Nitsotolis T, Athanasiou K, Myrodia MD, Kyriakoulis K, Trontzas I, Arfara-Melanini M, Kolonia V, Kityo C, Mugerwa H, Lukaakome J, Nsereko C, Lubega G, Kibirige M, Nakahima W, Wangi D, Aguti E, Generous L, Massa R, Nalaki M, Magala F, Nabaggala PK, Kityo C, Mugerwa H, Faith OD, Florence A, Emmanuel O, Beacham MP, Geoffrey A, Nakiboneka D, Apiyo P, Kiweewa F, Kirenga B, Kimuli I, Atukunda A, Muttamba W, Remmy K, Segawa I, Pheona N, Kigere D, Mbabazi QL, Boersalino L, Nyakoolo G, Kiweewa F, Fred A, Alupo A, Ebong D, Monday E, Nalubwama RN, Kainja M, Ambrose M, Kwehayo V, Nalubega MG, Ongoli A, Obbo S, Alaba J, Magombe G, Tino H, Obonya E, Lutaakome J, Kitonsa J, Onyango M, Naboth T, Naluyinda H, Nanyunja R, Irene M, Jane B, Wimfred K, Leonar S, Deus T, Babra N, Taire P, Lutaakone J, Nabankema E, Ogavu J, Mugerwa O, Okoth I, Mwebaze R, Mugabi T, Makhoba A, Arikiriza P, Theresa N, Nakayima H, Frank K, Ramgi P, Pereira K, Osinusi A, Cao H, Stumpp M, Goncalves S, Ramanathan K, Baseler B, Holley HP, Jankelevich S, Adams A, Becker N, Dolney S, Hissey D, Simpson S, Kim MH, Beeler J, Harmon L, Asomah M, Jato Y, Stottlemyer A, Tang O, Vanderpuye S, Yeon L, Buehn M, Eccard-Koons V, Frary S, MacDonald L, Cash J, Hoopengardner L, Linton J, Schaffhauser M, Nelson M, Spinelli-Nadzam M, Proffitt C, Lee C, Engel T, Fontaine L, Osborne CK, Hohn M, Galcik M, Thompson D, Chang W, Sherman BT, Rupert AW, Baseler M, Lallemand P, Imamichi T, Paudel S, Cook K, Haupt K, Highbarger J, Hazen A, Badralmaa Y, Smith K, Patel B, Kubernac R, Hoover ML, Brown C, DuChateau N, Ellis S, Flosi A, Fox L, Johnson L, Nelson R, Stojanovic J, Treagus A, Wenner C, Williams R (2022) Efficacy and safety of ensovibep for adults hospitalized with COVID-19: a randomized controlled trial. Ann Intern Med 175:1266–1274. https://doi.org/10.7326/M22-1503
Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, Smith EC, Case JB, Feng JY, Jordan R, Ray AS, Cihlar T, Siegel D, Mackman RL, Clarke MO, Baric RS, Denison MR (2018) Coronavirus susceptibility to the antiviral is mediated by the viral polymerase and the proofreading exoribonuclease. mBio 9:e00221-18. https://doi.org/10.1128/mBio.00221-18
Agrawal U, Raju R, Udwadia ZF (2020) Favipiravir: a new and emerging antiviral option in COVID-19. Med J Armed Forces India 76:370–376. https://doi.org/10.1016/j.mjafi.2020.08.004
Ahmed MH, Hassan A (2020) Dexamethasone for the treatment of coronavirus disease (COVID-19): a review. SN Compr Clin Med 2:2637–2646. https://doi.org/10.1007/s42399-020-00610-8
Banji D, Alqahtani SS, Banji OJF, Machanchery S, Shoaib A (2021) Calming the inflammatory storm in severe COVID-19 infections: role of biologics- a narrative review. Saudi Pharm J 29:213–222. https://doi.org/10.1016/j.jsps.2021.01.005
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez De Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh M, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC (2020) Remdesivir for the treatment of Covid-19 — final report. N Engl J Med 383:1813–1826. https://doi.org/10.1056/NEJMoa2007764
Bhatt K, Garimella R, Taugir R, Mehta I, Jamal M, Vijayan R, Offor R, Nwankwo K, Arif U, Waheed K, Kumari P, Lathiya M, Michel G, Pandya N, Halpern J, Nasir H, Sanchez-Gonzalez MA (2021) Effectiveness of mavrilimumab in viral infections including SARS-CoV-2 infection - a brief review. Infect Chemother 53:1. https://doi.org/10.3947/ic.2020.0109
Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, Mourão MPG, Brito-Sousa JD, Baía-da-Silva D, Guerra MVF, Hajjar LA, Pinto RC, Balieiro AAS, Pacheco AGF, Santos JDO, Naveca FG, Xavier MS, Siqueira AM, Schwarzbold A, Croda J, Nogueira ML, Romero GAS, Bassat Q, Fontes CJ, Albuquerque BC, Daniel-Ribeiro C-T, Monteiro WM, Lacerda MVG, for the CloroCovid-19 Team (2020) Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. JAMA Netw Open 3:e208857. https://doi.org/10.1001/jamanetworkopen.2020.8857
Bradbury CA, McQuilten Z (2022) Anticoagulation in COVID-19. The Lancet 399:5–7. https://doi.org/10.1016/S0140-6736(21)02503-4
Burhan E, Syahruddin E, Isbaniah F, Desianti GA, Fachrucha F, Sari CYI, Ismail E, Astuti P, Maruli MF, Mubarak F, Rengganis AT, Bilqis HH, Taslim I, Sastria E, Wiyarta E (2023) Evaluation of safety and effectiveness of remdesivir in treating COVID-19 patients after emergency use authorization study. Front Pharmacol 14:1205238. https://doi.org/10.3389/fphar.2023.1205238
Cao Y, Wei J, Zou L, Jiang T, Wang G, Chen L, Huang L, Meng F, Huang L, Wang N, Zhou X, Luo H, Mao Z, Chen X, **e J, Liu J, Cheng H, Zhao J, Huang G, Wang W, Zhou J (2020) Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol 146:137-146.e3. https://doi.org/10.1016/j.jaci.2020.05.019
Cao Z, Gao W, Bao H, Feng H, Mei S, Chen P, Gao Y, Cui Z, Zhang Q, Meng X, Gui H, Wang W, Jiang Y, Song Z, Shi Y, Sun J, Zhang Y, **e Q, Xu Y, Ning G, Gao Y, Zhao R (2023) VV116 versus nirmatrelvir–ritonavir for oral treatment of Covid-19. N Engl J Med 388:406–417. https://doi.org/10.1056/NEJMoa2208822
Cavalli G, Farina N, Campochiaro C, De Luca G, Della-Torre E, Tomelleri A, Dagna L (2020) Repurposing of biologic and targeted synthetic anti-rheumatic drugs in COVID-19 and hyper-inflammation: a comprehensive review of available and emerging evidence at the peak of the pandemic. Front Pharmacol 11:598308. https://doi.org/10.3389/fphar.2020.598308
Chamlagain R, Shah S, Sharma Paudel B, Dhital R, Kandel B (2021) Efficacy and safety of sarilumab in COVID-19: a systematic review. Interdiscip Perspect Infect Dis 2021:1–8. https://doi.org/10.1155/2021/8903435
Chavda VP, Patel AB, Vaghasiya DD (2022) SARS-CoV-2 variants and vulnerability at the global level. J Med Virol 94:2986–3005. https://doi.org/10.1002/jmv.27717
Chen Y, Li M-X, Lu G-D, Shen H-M, Zhou J (2021) Hydroxychloroquine/chloroquine as therapeutics for COVID-19: truth under the mystery. Int J Biol Sci 17:1538–1546. https://doi.org/10.7150/ijbs.59547
Cremer PC, Abbate A, Hudock K, McWilliams C, Mehta J, Chang SY, Sheng CC, Van Tassell B, Bonaventura A, Vecchié A, Carey B, Wang Q, Wolski KE, Rajendram P, Duggal A, Wang TS, Paolini JF, Trapnell BC, Gladish D, Myers K, Kuramochi Y, Sewell C, Balog C, Kosty Sweeny D, Kandrac J, Spencer S, Goyanes A, Sahoo D, Dugar S, Aguillon Prada R, Nichols D, Celiberti J, Partisano A, Fang F, Coehlo J, Perrin R, Mandell B, Gordon S, Wiedemann H, Young J, Greer J, Ho A-C, Ladd A, Mihalick V, Montpetit A, O’Brine J, Owen C, Pal M, Priday A, Raj Sedhai Y, Wohlford G, Hummel N, Korbee L (2021) Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Rheumatol 3:e410–e418. https://doi.org/10.1016/S2665-9913(21)00070-9
Criner GJ, Lang FM, Gottlieb RL, Mathews KS, Wang TS, Rice TW, Madduri D, Bellam S, Jeanfreau R, Case AH, Glassberg MK, Lyon GM, Ahmad K, Mendelson R, DiMaio JM, Tran MP, Spak CW, Abbasi JA, Davis SG, Ghamande S, Shen S, Sherman L, Lowry S (2022) Anti-granulocyte–macrophage colony–stimulating factor monoclonal antibody gimsilumab for COVID-19 pneumonia: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 205:1290–1299. https://doi.org/10.1164/rccm.202108-1859OC
Dauner DG, Dauner KN (2021) Summary of adverse drug events for hydroxychloroquine, azithromycin, and chloroquine during the COVID-19 pandemic. J Am Pharm Assoc 61:293–298. https://doi.org/10.1016/j.japh.2021.01.007
Du P, Geng J, Wang F, Chen X, Huang Z, Wang Y (2021) Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome. Int J Med Sci 18:1356–1362. https://doi.org/10.7150/ijms.53564
El Bairi K, Trapani D, Petrillo A, Le Page C, Zbakh H, Daniele B, Belbaraka R, Curigliano G, Afqir S (2020) Repurposing anticancer drugs for the management of COVID-19. Eur J Cancer 141:40–61. https://doi.org/10.1016/j.ejca.2020.09.014
Eltayb WA, Abdalla M, Rabie AM (2023) Novel investigational anti-SARS-CoV-2 agent ensitrelvir “S-217622”: a very promising potential universal broad-spectrum antiviral at the therapeutic frontline of coronavirus species. ACS Omega 8:5234–5246. https://doi.org/10.1021/acsomega.2c03881
Fanlo P, Gracia-Tello BDC, Fonseca Aizpuru E, Álvarez-Troncoso J, Gonzalez A, Prieto-González S, Freire M, Argibay AB, Pallarés L, Todolí JA, Pérez M, Buján-Rivas S, Ibáñez B, GEAS-SEMI Group, Arnáez R, Huarte E, Sanchez J, Zabalza E, Garcia-Rey R, Gonzalo M, Diez-Galán L, De La Rica-Escuín M, Martinez-Lostao L, Marín Ballvé A, Taboada-Martínez ML, Pampín-Sánchez R, Helguera-Amézua C, Fernández-Madera-Martínez R, García-Coya E, Álvarez-Suarez AM, Robles Á, Noblejas A, Soto C, Martínez E, Arnalich F, Arévalo C, López-Rodríguez A, Cobeta P, Hidalgo F, Diz S, González P, Bara N, Fabregate M, Jiménez J, Zhilina S, Pellicer-Ariño M, Rodríguez-Núñez O, Ribot-Grabalosa J, Costafreda-Mas M, Tomé-Pérez A, Hospital-Vidal T, Ladino-Vázquez A, Morancho-Sesé A, Salazar-Rustarazo A, Gabara-Xancó C, Gonzalez-Quintela A, Sopeña B, Alende-Sixto R, Esteban H, Rodriguez-Nuñez N, Andrade-Piña AH, Sanchidrian-Chapinal MÁ, Varela P, Taboada M, Maure-Noia B, López-Domínguez A, Filloy-Mato C, Gimena-Reyes B, Samartín-Ucha M, Vázquez-Triñanes C, Fernández-Martín J, Paradela-Carreiro A, Regueira-Arcay AM, Esteban-Marcos E, Martin-Pena L, Fernández-Navarro JA, Abdilla-Bonias N, Mestre-Torres J, Marques-Soares JR, Pardos-Gea J (2023) Efficacy and safety of anakinra plus standard of care for patients with severe COVID-19: a randomized phase 2/3 clinical trial. JAMA Netw Open 6:e237243. https://doi.org/10.1001/jamanetworkopen.2023.7243
Ganta N, Alnabwani D, Keating S, Patel V, Bommu VJL, Dawoud R, Cheriyath P (2022) Rare adverse events related to nivolumab, an immune checkpoint inhibitor: a case series. Cureus. https://doi.org/10.7759/cureus.22070
Goker Bagca B, Biray Avci C (2020) The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19. Cytokine Growth Factor Rev 54:51–61. https://doi.org/10.1016/j.cytogfr.2020.06.013
Heo Y-A (2022) Sotrovimab: first approval. Drugs 82:477–484. https://doi.org/10.1007/s40265-022-01690-7
Holubar M, Subramanian A, Purington N, Hedlin H, Bunning B, Walter KS, Bonilla H, Boumis A, Chen M, Clinton K, Dewhurst L, Epstein C, Jagannathan P, Kaszynski RH, Panu L, Parsonnet J, Ponder EL, Quintero O, Sefton E, Singh U, Soberanis L, Truong H, Andrews JR, Desai M, Khosla C, Maldonado Y (2022) Favipiravir for treatment of outpatients with asymptomatic or uncomplicated coronavirus disease 2019: a double-blind, randomized, placebo-controlled, phase 2 trial. Clin Infect Dis 75:1883–1892. https://doi.org/10.1093/cid/ciac312
Hossen MdS, Barek MA, Jahan N, Safiqul Islam M (2020) A review on current repurposing drugs for the treatment of COVID-19: reality and challenges. SN Compr Clin Med 2:1777–1789. https://doi.org/10.1007/s42399-020-00485-9
Huang Y, Yang C, Xu X, Xu W, Liu S (2020) Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin 41:1141–1149. https://doi.org/10.1038/s41401-020-0485-4
Hung IF-N, Lung K-C, Tso EY-K, Liu R, Chung TW-H, Chu M-Y, Ng Y-Y, Lo J, Chan J, Tam AR, Shum H-P, Chan V, Wu AK-L, Sin K-M, Leung W-S, Law W-L, Lung DC, Sin S, Yeung P, Yip CC-Y, Zhang RR, Fung AY-F, Yan EY-W, Leung K-H, Ip JD, Chu AW-H, Chan W-M, Ng AC-K, Lee R, Fung K, Yeung A, Wu T-C, Chan JW-M, Yan W-W, Chan W-M, Chan JF-W, Lie AK-W, Tsang OT-Y, Cheng VC-C, Que T-L, Lau C-S, Chan K-H, To KK-W, Yuen K-Y (2020) Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. The Lancet 395:1695–1704. https://doi.org/10.1016/S0140-6736(20)31042-4
Joyce RP, Hu VW, Wang J (2022) The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations. Med Chem Res 31:1637–1646. https://doi.org/10.1007/s00044-022-02951-6
Keystone E, Omair MA (2015) Chapter 62: Interleukin-6 inhibition, in: Rheumatology (6th Edition). Elsevier, Volume 1, pp 485–491. https://doi.org/10.1016/B978-0-323-09138-1.00062-0
Khani E, Shahrabi M, Rezaei H, Pourkarim F, Afsharirad H, Solduzian M (2022) Current evidence on the use of anakinra in COVID-19. Int Immunopharmacol 111:109075. https://doi.org/10.1016/j.intimp.2022.109075
Koseki T, Nakajima K, Iwasaki H, Yamada S, Takahashi K, Doi Y, Mizuno T (2022) Baseline uric acid levels and steady-state favipiravir concentrations are associated with occurrence of hyperuricemia among COVID-19 patients. Int J Infect Dis 115:218–223. https://doi.org/10.1016/j.ijid.2021.12.324
Lescure F-X, Honda H, Fowler RA, Lazar JS, Shi G, Wung P, Patel N, Hagino O, Bazzalo IJ, Casas MM, Nuñez SA, Pere Y, Ibarrola CM, Solis Aramayo MA, Cuesta MC, Duarte AE, Gutierrez Fernandez PM, Iannantuono MA, Miyazaki EA, Silvio JP, Scublinsky DG, Bales A, Catarino D, Fiss E, Mohrbacher S, Sato V, Baylao A, Cavalcante A, Correa F, De Andrade CA, Furtado J, Ribeiro Filho N, Telles V, Trevelin LT, Vipich R, Boldo R, Borges P, Lobo S, Luckemeyer G, Machado L, Alves MB, Iglessias AC, Lago MM, Santos DW, Chapdelaine H, Falcone EL, Jamal R, Luong M-L, Durand M, Doucet S, Carrier F-M, Coburn BA, Del Sorbo L, Walmsley SL, Belga S, Chen LY, Mah AD, Steiner T, Wright AJ, Hajek J, Adhikari N, Fowler RA, Daneman N, Khwaja KA, Shahin J, Gonzalez C, Silva R, Lindh M, Maluenda G, Fernandez P, Oyonarte M, Lasso M, Boyer A, Bronnimann D, Bui H-N, Cazanave C, Chaussade H, Desclaux A, Ducours M, Duvignaud A, Malvy D, Martin L, Neau D, Nguyen D, Pistone T, Soubrane-Wirth G, Leitao J, Allavena C, Biron C, Bouchez S, Gaborit B, Gregoire A, Le Turnier P, Lecompte A-S, Lecomte R, Lefebvre M, Raffi F, Boutoille D, Morineau PH, Guéry R, Chatelus E, Dumoussaud N, Felten R, Luca F, Goichot B, Schneider F, Taquet M-C, Groh M, Roumier M, Neuville M, Bachelard A, Isernia V, Lescure F-X, Phung B-C, Rachline A, Sautereau A, Vallois D, Bleher Y, Boucher D, Coudon C, Esnault J, Guimard T, Leautez-Nainville S, Merrien D, Morrier M, Motte-Vincent P, Gabeff R, Leclerc H, Cozic C, Decours R, Février R, Colin G, Abgrall S, Vignes D, Sterpu R, Kuellmar M, Meersch-Dini M, Weiss R, Zarbock A, Antony C, Berger M, Brenner T, Taube C, Herbstreit F, Dolff S, Konik M, Schmidt K, Zettler M, Witzke O, Boell B, Garcia Borrega J, Koehler P, Zander T, Dusse F, Al-Sawaf O, Köhler P, Eichenauer D, Kochanek M, Shimabukuro-Vornhagen A, Mellinghoff S, Claßen A, Heger J-M, Meyer-Schwickerath C, Liedgens P, Heindel K, Belkin A, Biber A, Gilboa M, Levy I, Litachevsky V, Rahav G, Finesod Wiedner A, Zilberman-Daniels T, Oster Y, Strahilevitz J, Sviri S, Baldissera EM, Campochiaro C, Cavalli G, Dagna L, De Luca G, Della Torre E, Tomelleri A, Bernasconi De Luca D, Capetti AF, Coen M, Cossu MV, Galli M, Giacomelli A, Gubertini GA, Rusconi S, Burastero GJ, Digaetano M, Guaraldi G, Meschiari M, Mussini C, Puzzolante C, Volpi S, Aiello M, Ariani A, Chetta AA, Frizzelli A, Ticinesi A, Tuttolomondo D, Aliberti S, Blasi FB, Di Pasquale MF, Misuraca S, Pilocane T, Simonetta E, Aghelmo AM, Angelini C, Brunetta E, Canonica GW, Ciccarelli M, Dal Farra S, De Santis M, Ferri S, Folci M, Guidelli GM, Heffler EM, Loiacono F, Malipiero G, Paoletti G, Pedale R, Puggioni FA, Racca F, Zumbo A, Satou M, Honda H, Lisun T, Protsenko D, Rubtsov N, Beloglazova I, Fomina D, Lysenko M, Serdotetskova S, Firstov V, Gordeev I, Kokorin I, Komissarova K, Lapochkina N, Luchinkina E, Malimon V, Mamedguseyinova S, Polubatonova K, Suvorova N, Arribas J, Borobia Perez AM, De La Calle Prieto F, Figueira JC, Motejano Sanchez R, Mora-Rillo M, Prados Sanchez C, Queiruga Parada J, Fernandez Arnalich F, Guerro Barrientos M, Bendala Estrada A, Caballero Marcos A, Garcia Leoni ME, García-Martínez R, Collado AM, Munoz Garcia P, TorresDoRego A, VillalbaGarcía MV, Burrillo A, ValerioMinero M, GijonVidaurreta P, InfanteHerrero S, Velilla E, Machado M, Olmedo M, Pinilla B, AlmiranteGragera B, CañasRuano MDLE, ContrerasMedina S, CortésHerrera A, FalcóFerrer V, FerrerRoca R, NuvialsCasals X, RiberaPascuet E, SuanzesDiez P, RebolloCastro P, GarciaAlcaide F, Soriano A, OliverCaldes A, GonzálezCordón A, Cardozo C, De La MoraCañizo L, PenaLópez R, Chamorro S, Crespillo-Andujar C, EscuderoSanchez R, Fortún-Abete J, Monge-Maillo B, MorenoZamora A, Norman F, SanchezConde M, SerranoVillar S, Vizcarra P (2021) Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 9(522):532. https://doi.org/10.1016/S2213-2600(21)00099-0
Lim EHT, Vlaar APJ, Brouwer MC, Van De Beek D (2023) Inhibiting C5 in patients with severe COVID-19—the incorrect target? Lancet Respir Med 11:e80. https://doi.org/10.1016/S2213-2600(23)00189-3
Lin HXJ, Cho S, Meyyur Aravamudan V, Sanda HY, Palraj R, Molton JS, Venkatachalam I (2021) Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence. Infection 49:401–410. https://doi.org/10.1007/s15010-020-01557-7
Magro P, Zanella I, Pescarolo M, Castelli F, Quiros-Roldan E (2021) Lopinavir/ritonavir: repurposing an old drug for HIV infection in COVID-19 treatment. Biomed J 44:43–53. https://doi.org/10.1016/j.bj.2020.11.005
Mali KR, Eerike M, Raj GM, Bisoi D, Priyadarshini R, Ravi G, Chaliserry LF, Janti SS (2023) Efficacy and safety of molnupiravir in COVID-19 patients: a systematic review. Ir J Med Sci 1971–192:1665–1678. https://doi.org/10.1007/s11845-022-03139-y
Manabe T, Kambayashi D, Akatsu H, Kudo K (2021) Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. BMC Infect Dis 21:489. https://doi.org/10.1186/s12879-021-06164-x
Marzi M, Vakil MK, Bahmanyar M, Zarenezhad E (2022) Paxlovid: mechanism of action, synthesis, and in silico study. BioMed Res Int 2022:1–16. https://doi.org/10.1155/2022/7341493
Mazaherpour H, Sofian M, Farahani E, Abdi A, Mazaherpour S, Bavand A, Ramezani A (2022) Comparing outcomes of two antiviral therapy combinations among COVID-19 Patients. Biomed Res Int 2022:1522426. https://doi.org/10.1155/2022/1522426
Mody V, Ho J, Wills S, Mawri A, Lawson L, Ebert MCCJC, Fortin GM, Rayalam S, Taval S (2021) Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents. Commun Biol 4:93. https://doi.org/10.1038/s42003-020-01577-x
Mohan A, Tiwari P, Suri TM, Mittal S, Patel A, Jain A, Velpandian T, Das US, Boppana TK, Pandey RM, Shelke SS, Singh AR, Bhatnagar S, Masih S, Mahajan S, Dwivedi T, Sahoo B, Pandit A, Bhopale S, Vig S, Gupta R, Madan K, Hadda V, Gupta N, Garg R, Meena VP, Guleria R (2021) Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial. J Infect Chemother 27(12):1743–1749. https://doi.org/10.1016/j.jiac.2021.08.021
Mouffak S, Shubbar Q, Saleh E, El-Awady R (2021) Recent advances in management of COVID-19: a review. Biomed Pharmacother 143:112107. https://doi.org/10.1016/j.biopha.2021.112107
Nguyen T, Dima L, Willett KC (2023) Anakinra—an interleukin-1 receptor antagonist for COVID-19. Am J Ther 30:e108–e116. https://doi.org/10.1097/MJT.0000000000001603
Nojomi M, Yassin Z, Keyvani H, Makiani MJ, Roham M, Laali A, Dehghan N, Navaei M, Ranjbar M (2020) Effect of Arbidol (umifenovir) on COVID-19: a randomized controlled trial. BMC Infect Dis 20:954. https://doi.org/10.1186/s12879-020-05698-w
Noreen S, Maqbool I, Madni A (2021) Dexamethasone: therapeutic potential, risks, and future projection during COVID-19 pandemic. Eur J Pharmacol 894:173854. https://doi.org/10.1016/j.ejphar.2021.173854
Nortey RA, Kretchy IA, Koduah A, Buabeng KO (2023) Biopsychosocial analysis of antibiotic use for the prevention or management of COVID-19 infections: a sco** review. Res Soc Adm Pharm 19:573–581. https://doi.org/10.1016/j.sapharm.2022.11.011
Nukoolkarn V, Lee VS, Malaisree M, Aruksakulwong O, Hannongbua S (2008) Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CLpro inhibitors. J Theor Biol 254:861–867. https://doi.org/10.1016/j.jtbi.2008.07.030
Olender SA, Perez KK, Go AS, Balani B, Price-Haywood EG, Shah NS, Wang S, Walunas TL, Swaminathan S, Slim J, Chin B, De Wit S, Ali SM, Soriano Viladomiu A, Robinson P, Gottlieb RL, Tsang TYO, Lee I-H, Hu H, Haubrich RH, Chokkalingam AP, Lin L, Zhong L, Bekele BN, Mera-Giler R, Phulpin C, Edgar H, Gallant J, Diaz-Cuervo H, Smith LE, Osinusi AO, Brainard DM, Bernardino JI, GS-US-540–5773 and GS-US-540–5807 Investigators (2021) Remdesivir for severe coronavirus disease 2019 (COVID-19) versus a cohort receiving standard of care. Clin Infect Dis 73:e4166–e4174. https://doi.org/10.1093/cid/ciaa1041
Pandey S, Pathak SK, Pandey A, Salunke AA, Chawla J, Sharma A, Sharma S, Thivari P, Ratna HVK (2020) Ivermectin in COVID-19: what do we know? Diabetes Metab. Syndr Clin Res Rev 14:1921–1922. https://doi.org/10.1016/j.dsx.2020.09.027
Parasher A (2021) COVID-19: current understanding of its pathophysiology, clinical presentation and treatment. Postgrad Med J 97:312–320. https://doi.org/10.1136/postgradmedj-2020-138577
Patnaik MM, Sallman DA, Mangaonkar AA, Heuer R, Hirvela J, Zblewski D, Al-Kali A, Binder M, Balasis ME, Newman H, Letson C, Kruer TL, Gangat N, Komrokji RS, Tefferi A, Lo A, Shih T, Durrant C, List AF, Padron E (2020) Phase 1 study of lenzilumab, a recombinant anti–human GM-CSF antibody, for chronic myelomonocytic leukemia. Blood 136:909–913. https://doi.org/10.1182/blood.2019004352
Pourkarim F, Pourtaghi-Anvarian S, Rezaee H (2022) Molnupiravir: a new candidate for COVID-19 treatment. Pharmacol Res Perspect 10:e00909. https://doi.org/10.1002/prp2.909
Prins MLM, Van Der Plas JL, Vissers MFJM, Berends CL, Tresch G, Soergel M, Fernández E, Van Den Berge N, Duijsings D, Zitt C, Stavropoulou V, Zimmermann M, Drake RF, Burggraaf J, Groeneveld GH, Kamerling IMC (2023) Viral clearance, pharmacokinetics and tolerability of ensovibep in patients with mild to moderate COVID-19: a phase 2a, open-label, single-dose escalation study. Br J Clin Pharmacol 89:1105–1114. https://doi.org/10.1111/bcp.15560
Punekar M, Kshirsagar M, Tellapragada C, Patil K (2022) Repurposing of antiviral drugs for COVID-19 and impact of repurposed drugs on the nervous system. Microb Pathog 168:105608. https://doi.org/10.1016/j.micpath.2022.105608
Rafaniello C, Ferrajolo C, Sullo MG, Gaio M, Zinzi A, Scavone C, Gargano F, Coscioni E, Rossi F, Capuano A (2021) Cardiac events potentially associated to remdesivir: an analysis from the European Spontaneous Adverse Event Reporting System. Pharmaceuticals 14:611. https://doi.org/10.3390/ph14070611
Reis G, Moreira Silva EADS, Medeiros Silva DC, Thabane L, Singh G, Park JJH, Forrest JI, Harari O, Quirino Dos Santos CV, Guimarães De Almeida APF, Figueiredo Neto ADD, Savassi LCM, Milagres AC, Teixeira MM, Simplicio MIC, Ribeiro LB, Oliveira R, Mills EJ, TOGETHER Investigators (2021) Effect of early treatment with hydroxychloroquine or lopinavir and ritonavir on risk of hospitalization among patients with COVID-19: the TOGETHER randomized clinical trial. JAMA Netw Open 4:e216468. https://doi.org/10.1001/jamanetworkopen.2021.6468
Rosas IO, Diaz G, Gottlieb RL, Lobo SM, Robinson P, Hunter BD, Cavalcante AW, Overcash JS, Hanania NA, Skarbnik A, Garcia-Diaz J, Gordeev I, Carratalà J, Gordon O, Graham E, Lewin-Koh N, Tsai L, Tuckwell K, Cao H, Brainard D, Olsson JK (2021) Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial. Intensive Care Med 47:1258–1270. https://doi.org/10.1007/s00134-021-06507-x
Satarker S, Ahuja T, BanerjeeEDograAgarwalNampoothiri MVBSTM (2020) Hydroxychloroquine in COVID-19: potential mechanism of action against SARS-CoV-2. Curr Pharmacol Rep 6:203–211. https://doi.org/10.1007/s40495-020-00231-8
Schwartz RA, Suskind RM (2020) Azithromycin and COVID-19: Prompt early use at first signs of this infection in adults and children, an approach worthy of consideration. Dermatol Ther 33(4):e13785. https://doi.org/10.1111/dth.13785
Shah PL, Orton CM, Grinsztejn B, Donaldson GC, Crabtree Ramírez B, Tonkin J, Santos BR, Cardoso SW, Ritchie AI, Conway F, Riberio MPD, Wiseman DJ, Tana A, Vijayakumar B, Caneja C, Leaper C, Mann B, Samson A, Bhavsar PK, Boffito M, Johnson MR, Pozniak A, Pelly M, Foster D, Shabbir N, Connolly S, Cartier A, Jaffer S, Winpenny C, Daby D, Pepper S, Adamson C, Carungcong J, Nundlall K, Fedele S, Samson-Fessale P, Schoolmeesters A, De Almeida G, Martins L, Bull R, Correia Da Costa P, Bautista C, Eleanor Flores M, Maheswaran S, Macabodbod L, Houseman R, Svensson M-L, Sayan A, Fung C, Garner J, Lai D, Nelson M, Moore L, Gidwani S, Davies G, Ouma B, Salinos C, Salha J, Yassein R, Abbasi A, Oblak M, Steward A, Thankachen M, Barker A, Fernandes C, Beatriz V, Flores L, Soler-Carracedo A, Rocca A, Maheswaran S, Martella C, Lloyd C, Nolan C, Horsford L, Martins L, Thomas L, Winstanley M, Bourke M, Branch N, Orhan O, Morton R, Saunder S, Patil S, Hughes S, Zhe W, De Leon A, Farah A, Rya G, Alizadeh K, Leong K, Trepte L, Goel N, McGown P, Kirwan U, Vilela Baião T, Marins L, Nazer S, Malaguthi De Souza R, Feitosa M, Lessa F, Silva De Magalhães E, Costenaro J, De CassiaAlvesLira R, Carolina A, CauduroDe Castro A, MachadoDaSilva A, Kliemann D, De CassiaAlvesLira R, Walker G, Norton D, Lowthorpe V, Ivan M, Lillie P, Easom N, Sierra Madero J, LópezIñiguez Á, PatriciaMuñuzuri Nájera G, PaolaAlarcónMurra C, Alanis Vega A, MuñozTrejo T, PérezRodríguez O (2023) Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care. Lancet Respir Med 11:415–424. https://doi.org/10.1016/S2213-2600(22)00412-X
Shapiro AE, Sarkis E, Acloque J, Free A, Gonzalez-Rojas Y, Hussain R, Juarez E, Moya J, Parikh N, Inman D, Cebrik D, Nader A, Noormohamed N, Wang Q, Skingsley A, Austin D, Peppercorn A, Agostini ML, Parra S, Chow S, Mogalian E, Pang PS, Hong DK, Sager JE, Yeh WW, Alexander EL, Gaffney LA, Kohli A (2023) Intramuscular vs intravenous SARS-CoV-2 neutralizing antibody sotrovimab for treatment of COVID-19 (COMET-TAIL): a randomized noninferiority clinical trial. Open Forum Infect Dis 10:ofad354. https://doi.org/10.1093/ofid/ofad354
Shimizu R, Sonoyama T, Fukuhara T, Kuwata A, Matsuo Y, Kubota R (2022) Safety, tolerability, and pharmacokinetics of the novel antiviral agent ensitrelvir fumaric acid, a SARS-CoV-2 3CL protease inhibitor, in healthy adults. Antimicrob Agents Chemother 66:e00632-e722. https://doi.org/10.1128/aac.00632-22
Shuter J (2008) Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. Ther Clin Risk Manag 4:1023–1033. https://doi.org/10.2147/TCRM.S3285
Singh TU, Parida S, Lingaraju MC, Kesavan M, Kumar D, Singh RK (2020) Drug repurposing approach to fight COVID-19. Pharmacol Rep 72:1479–1508. https://doi.org/10.1007/s43440-020-00155-6
Sinha N, Balayla G (2020) Hydroxychloroquine and COVID-19. Postgrad Med J 96:550–555. https://doi.org/10.1136/postgradmedj-2020-137785
Syed YY (2021) Ravulizumab: a review in atypical haemolytic uraemic syndrome. Drugs 81:587–594. https://doi.org/10.1007/s40265-021-01481-6
Temesgen Z, Burger CD, Baker J, Polk C, Libertin C, Kelley C, Marconi VC, Orenstein R, Durrant C, Chappell D, Ahmed O, Chappell G, Badley AD (2021) Lenzilumab efficacy and safety in newly hospitalized COVID-19 subjects: results from the live-air phase 3 randomized double-blind placebo-controlled trial. medRxiv. https://doi.org/10.1101/2021.05.01.21256470
Tharaux P-L, Pialoux G, Pavot A, Mariette X, Hermine O, Resche-Rigon M, Porcher R, Ravaud P, Bureau S, Dougados M, Tibi A, Azoulay E, Cadranel J, Emmerich J, Fartoukh M, Guidet B, Humbert M, Lacombe K, Mahevas M, Pene F, Pourchet-Martinez V, Schlemmer F, Yazdanpanah Y, Baron G, Perrodeau E, Vanhoye D, Kedzia C, Demerville L, Gysembergh-Houal A, Bourgoin A, Dalibey S, Raked N, Mameri L, Alary S, Hamiria S, Bariz T, Semri H, Hai DM, Benafla M, Belloul M, Vauboin P, Flamand S, Pacheco C, Walter-Petrich A, Stan E, Benarab S, Nyanou C, Montlahuc C, Biard L, Charreteur R, Dupré C, Cardet K, Lehmann B, Baghli K, Madelaine C, D’Ortenzio E, Puéchal O, Semaille C, Savale L, Harrois A, Figueiredo S, Duranteau J, Anguel N, Monnet X, Richard C, Teboul J-L, Durand P, Tissieres P, Jevnikar M, Montani D, Bulifon S, Jaïs X, Sitbon O, Pavy S, Noel N, Lambotte O, Escaut L, Jauréguiberry S, Baudry E, Verny C, Noaillon M, Lefèvre E, Zaidan M, Le Tiec CLT, Verstuyft CV, Roques A-M, Grimaldi L, Molinari D, Leprun G, Fourreau A, Cylly L, Virlouvet M, Meftali R, Fabre S, Licois M, Mamoune A, Boudali Y, Georgin-Lavialle S, Senet P, Soria A, Parrot A, François H, Rozensztajn N, Blin E, Choinier P, Camuset J, Rech J-S, Canellas A, Rolland-Debord C, Lemarié N, Belaube N, Nadal M, Siguier M, Petit-Hoang C, Chas J, Drouet E, Lemoine M, Phibel A, Aunay L, Bertrand E, Ravato S, Vayssettes M, Adda A, Wilpotte C, Thibaut P, Fillon J, Debrix I, Fellahi S, Bastard J-P, Lefèvre G, Fallet V, Gottenberg J-E, Hansmann Y, Andres E, Bayer S, Becker G, Blanc F, Brin S, Castelain V, Chatelus E, Chatron E, Collange O, Danion F, De Blay F, Demonsant E, Diemunsch P, Diemunsch S, Felten R, Goichot B, Greigert V, Guffroy A, Heger B, Hutt A, Kaeuffer C, Kassegne L, Korganow AS, Le Borgne P, Lefebvre N, Martin T, Mertes PM, Metzger C, Meyer N, Nisand G, Noll E, Oberlin M, Ohlmann-Caillard S, Poindron V, Pottecher J, Ruch Y, Sublon C, Tayebi H, Weill F, Mekinian A, Chopin D, Fain O, Garnier M, Krause Le Garrec J, Morgand M, Pacanowski J, Urbina T, McAvoy C, Pereira M, Aratus G, Berard L, Simon T, Daguenel-Nguyen A, Antignac M, Leplay C, Arlet J-B, Diehl J-L, Bellenfant F, Blanchard A, Buffet A, Cholley B, Fayol A, Flamarion E, Godier A, Gorget T, Hamada S-R, Hauw-Berlemont C, Hulot J-S, Lebeaux D, Livrozet M, Michon A, Neuschwander A, Penet M-A, Planquette B, Ranque B, Sanchez O, Volle G, Briois S, Cornic M, Elisee V, Jesuthasan D, Djadi-Prat J, Jouany P, Junquera R, Henriques M, Kebir A, Lehir I, Meunier J, Patin F, Paquet V, Tréhan A, Vigna V, Sabatier B, Bergerot D, Jouve C, Knosp C, Lenoir O, Mahtal N, Resmini L, Lescure F-X, Ghosn J, Bachelard A, Bironne T, Borie R, Bounhiol A, Boussard C, Chauffier J, Chalal S, Chalal L, Chansombat M, Crespin P, Crestani B, Daconceicao O, Deconinck L, Dieude P, Dossier A, Dubert M, Ducrocq G, Fuentes A, Gervais A, Gilbert M, Isernia V, Ismael S, Joly V, Julia Z, Lariven S, Le Gac S, Le Pluart D, Louni F, Ndiaye A, Papo T, Parisey M, Phung B, Pourbaix A, Rachline A, Rioux C, Sautereau A, Steg G, Tarhini H, Valayer S, Vallois D, Vermes P, Volpe T, Nguyen Y, Honsel V, Weiss E, Codorniu A, Zarrouk V, De Lastours V, Uzzan M, Olivier O, Rossi G, Gamany N, Rahli R, Louis Z, Boutboul D, Galicier L, Amara Y, Archer G, Benattia A, Bergeron A, Bondeelle L, De Castro N, Clément M, Darmont M, Denis B, Dupin C, Feredj E, Feyeux D, Joseph A, Lengliné E, Le Guen P, Liégeon G, Lorillon G, Mabrouki A, Mariotte E, Martin De Frémont G, Mirouse A, Molina J-M, Peffault De Latour R, Oksenhendler E, Saussereau J, Tazi A, Tudesq J-J, Zafrani L, Brindele I, Bugnet E, Celli Lebras K, Chabert J, Djaghout L, Fauvaux C, Jegu AL, Kozaliewicz E, Meunier M, Tremorin M-T, Davoine C, Madeleine I, Caillat-Zucman S, Delaugerre C, Morin F, Sene D, Burlacu R, Chousterman B, Megarbane B, Richette P, Riveline J-P, Frazier A, Vicaut E, Berton L, Hadjam T, Vasquez-Ibarra MA, Jourdaine C, Jacob A, Smati J, Renaud S, Manivet P, Pernin C, Suarez L, Semerano L, Abad S, Benainous R, Bloch Queyrat C, Bonnet N, Brahmi S, Cailhol J, Cohen Y, Comparon C, Cordel H, Dhote R, Dournon N, Duchemann B, Ebstein N, Giroux-Leprieur B, Goupil De Bouille J, Jacolot A, Nunes H, Oziel J, Rathouin V, Rigal M, Roulot D, Tantet C, Uzunhan Y, Costedoat-Chalumeau N, Ait Hamou Z, Benghanem S, Blanche P, Canoui E, Carlier N, Chaigne B, Contejean A, Dunogue B, Dupland P, Durel-Maurisse A, Gauzit R, Jaubert P, Joumaa H, Jozwiak M, Kerneis S, Lachatre M, Lafoeste H, Legendre P, Luong Nguyen LB, Marey J, Morbieu C, Mouthon L, Nguyen L, Palmieri L-J, Regent A, Szwebel T-A, Terrier B, Guerin C, Zerbit J, Cheref K, Chitour K, Cisse MS, Clarke A, Clavere G, Dusanter I, Gaudefroy C, Jallouli M, Kolta S, Le Bourlout C, Marin N, Menage N, Moores A, Peigney I, Pierron C, Saleh-Mghir S, Vallet M, Michel M, Melica G, Lelievre J-D, Fois E, Lim P, Matignon M, Guillaud C, Thiemele A, Schmitz D, Bouhris M, Belazouz S, Languille L, Mekontso-Dessaps A, Sadaoui T, Mayaux J, Cacoub P, Corvol J-C, Louapre C, Sambin S, Mariani L-L, Karachi C, Tubach F, Estellat C, Gimeno L, Martin K, Bah A, Keo V, Ouamri S, Messaoudi Y, Yelles N, Faye P, Cavelot S, Larcheveque C, Annonay L, Benhida J, Zahrate-Ghoul A, Hammal S, Belilita R, Lecronier M, Beurton A, Haudebourg L, Deleris R, Le Marec J, Virolle S, Nemlaghi S, Bureau C, Mora P, De Sarcus M, Clovet O, Duceau B, Grisot PH, Pari MH, Arzoine J, Clarac U, Faure M, Delemazure J, Decavele M, Morawiec E, Demoule A, Dres M, Vautier M, Allenbach Y, Benveniste O, Leroux G, Rigolet A, Guillaume-Jugnot P, Domont F, Desbois AC, Comarmond C, Champtiaux N, Toquet S, Ghembaza A, Vieira M, Maalouf G, Boleto G, Ferfar Y, Charbonnier F, Aguilar C, Alby-Laurent F, Alyanakian M-A, Bakouboula P, Broissand C, Burger C, Campos-Vega C, Chavarot N, Choupeaux L, Fournier B, Granville S, Issorat E, Rouzaud C, Vimpere D, Geri G, Derridj N, Sguiouar N, Meddah H, Djadel M, Chambrin-Lauvray H, Duclos-Vallée J-C, Saliba F, Sacleux S-C, Koumis I, Michot J-M, Stoclin A, Colomba E, Pommeret F, Willekens C, Sakkal M, Da Silva R, Dejean V, Mekid Y, Ben-Mabrouk I, Pradon C, Drouard L, Camara-Clayette V, Morel A, Garcia G, Mohebbi A, Berbour F, Dehais M, Pouliquen A-L, Klasen A, Soyez-Herkert L, London J, Keroumi Y, Guillot E, Grailles G, El Amine Y, Defrancq F, Fodil H, Bouras C, Dautel D, Gambier N, Dieye T, Razurel A, Bienvenu B, Lancon V, Lecomte L, Beziriganyan K, Asselate B, Allanic L, Kiouris E, Legros M-H, Lemagner C, Martel P, Provitolo V, Ackermann F, Le Marchand M, ClanHewWai A, Fremont D, Coupez E, Adda M, Duée F, Bernard L, Gros A, Henry E, Courtin C, Pattyn A, Guinot P-G, Bardou M, Maurer A, Jambon J, Cransac A, Pernot C, Mourvillier B, Servettaz A, Deslée G, Wynckel A, Benoit P, Marquis E, Roux D, Gernez C, Yelnik C, Poissy J, Nizard M, Denies F, Gros H, Mourad J-J, Sacco E, Renet S (2021) Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir Med 9:295–304. https://doi.org/10.1016/S2213-2600(20)30556-7
Toussi SS, Hammond JL, Gerstenberger BS, Anderson AS (2023) Therapeutics for COVID-19. Nat Microbiol 8:771–786. https://doi.org/10.1038/s41564-023-01356-4
Unoh Y, Uehara S, Nakahara K, Nobori H, Yamatsu Y, Yamamoto S, Maruyama Y, Taoda Y, Kasamatsu K, Suto T, Kouki K, Nakahashi A, Kawashima S, Sanaki T, Toba S, Uemura K, Mizutare T, Ando S, Sasaki M, Orba Y, Sawa H, Sato A, Sato T, Kato T, Tachibana Y (2022) Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19. J Med Chem 65:6499–6512. https://doi.org/10.1021/acs.jmedchem.2c00117
Van Laar SA, De Boer MGJ, Gombert-Handoko KB, Guchelaar H, Zwaveling J (2021) Liver and kidney function in patients with Covid-19 treated with remdesivir. Br J Clin Pharmacol 87:4450–4454. https://doi.org/10.1111/bcp.14831
Veiga VC, Prats JAGG, Farias DLC, Rosa RG, Dourado LK, Zampieri FG, Machado FR, Lopes RD, Berwanger O, Azevedo LCP, Avezum Á, Lisboa TC, Rojas SSO, Coelho JC, Leite RT, Carvalho JC, Andrade LEC, Sandes AF, Pintão MCT, Castro CG, Santos SV, De Almeida TML, Costa AN, Gebara OCE, De Freitas FGR, Pacheco ES, Machado DJB, Martin J, Conceição FG, Siqueira SRR, Damiani LP, Ishihara LM, Schneider D, De Souza D, Cavalcanti AB, Scheinberg P (2021) Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial.BMJ 372:n84. https://doi.org/10.1136/bmj.n84
Villaescusa L, Zaragozá F, Gayo-Abeleira I, Zaragozá C (2022) A new approach to the management of COVID-19. Antagonists of IL-6: siltuximab. Adv Ther 39:1126–1148. https://doi.org/10.1007/s12325-022-02042-3
Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG, Nichol ST (2005) Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2:69. https://doi.org/10.1186/1743-422X-2-69
Walser M, Rothenberger S, Hurdiss DL, Schlegel A, Calabro V, Fontaine S, Villemagne D, Paladino M, Hospodarsch T, Neculcea A, Cornelius A, Schildknecht P, Matzner M, Hänggi M, Franchini M, Kaufmann Y, Schaible D, Schlegel I, Iss C, Looser T, Mangold S, Herzog C, Schiegg D, Reichen C, Radom F, Bosshart A, Lehmann A, Haeuptle MA, Zürcher A, Vagt T, Sigrist G, Straumann M, Proba K, Veitonmäki N, Dawson KM, Zitt C, Mayor J, Ryter S, Lyoo H, Wang C, Li W, Drulyte I, Du W, Binz HK, De Waal L, Stittelaar KJ, Taplin S, Lewis S, Steiner D, Van Kuppeveld FJM, Engler O, Bosch B-J, Stumpp MT, Amstutz P (2020) Highly potent anti-SARS-CoV-2 multivalent DARPin therapeutic candidates (preprint). Immunology. https://doi.org/10.1101/2020.08.25.256339
Wang F, **ao W, Tang Y, Cao M, Shu D, Asakawa T, Xu Y, Jiang X, Zhang L, Wang W, Tang J, Huang Y, Yang Y, Yang Y, Tang R, Shen J, Lu H (2023) Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial. Lancet Reg Health - West Pac 38:100835. https://doi.org/10.1016/j.lanwpc.2023.100835
Wu R, Wang L, Kuo H-CD, Shannar A, Peter R, Chou PJ, Li S, Hudlikar R, Liu X, Liu Z, Poiani GJ, Amorosa L, Brunetti L, Kong A-N (2020) An update on current therapeutic drugs treating COVID-19. Curr Pharmacol Rep 6:56–70. https://doi.org/10.1007/s40495-020-00216-7
Zhan X, Dowell S, Shen Y, Lee DL (2020) Chloroquine to fight COVID-19: a consideration of mechanisms and adverse effects? Heliyon 6:e04900. https://doi.org/10.1016/j.heliyon.2020.e04900
Zhang S, Li L, Shen A, Chen Y, Qi Z (2020) Rational use of tocilizumab in the treatment of novel coronavirus pneumonia. Clin Drug Investig 40:511–518. https://doi.org/10.1007/s40261-020-00917-3
Zhao H, Zhu Q, Zhang C, Li J, Wei M, Qin Y, Chen G, Wang K, Yu J, Wu Z, Chen X, Wang G (2021) Tocilizumab combined with favipiravir in the treatment of COVID-19: a multicenter trial in a small sample size. Biomed Pharmacother 133:110825. https://doi.org/10.1016/j.biopha.2020.110825
Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Author information
Authors and Affiliations
Contributions
Vivek P. Chavda and Payal Dodiya wrote the main manuscript text and Vasso Apostolopoulos performed the critical review and enrichment of the manuscript. All authors reviewed the manuscript. The authors confirm that no paper mill and artificial intelligence were used.
Corresponding authors
Ethics declarations
Ethical approval
Not applicable.
Competing interests
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Chavda, V., Dodiya, P. & Apostolopoulos, V. Adverse drug reactions associated with COVID-19 management. Naunyn-Schmiedeberg's Arch Pharmacol (2024). https://doi.org/10.1007/s00210-024-03137-0
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00210-024-03137-0